Assignment history — US Patent 11261151

Inventors

Steven C. Quay (Atossa Therapeutics Inc.)
Yao-Lin Sun (Krisan Biotech Co Ltd)
Lunghu WANG (Krisan Biotech Co Ltd)
ChangJung Wu (Krisan Biotech Co Ltd)
ChuanDer Huang (Krisan Biotech Co Ltd)

Original assignee

Atossa Therapeutics Inc. is named as the original assignee on the issued patent. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for breast cancer and other breast conditions. They are actively engaged in developing endoxifen as a product, which embodies the claims of the patent. Atossa Therapeutics, Inc. is currently an operating company.

Assignment timeline

2020-11-10 (executed) / recorded 2020-11-10 — Reel 051783/0477
- Conveyance: Corrective Assignment to correct the change of name previously recorded.
- Assignor: Atossa Genetics Inc.
- Assignee: ATOSSA THERAPEUTICS, INC.
- Correspondent: Jennifer L. Camacho, Law Office of Jennifer L. Camacho, 2800 E. Madison Street, Suite 201, Seattle, WA 98112.
- Context: internal reorg
2021-11-23 (executed) / recorded 2021-11-23 — Reel 058199/0053
- Conveyance: Assignment of Assignors Interest
- Assignor: KRISAN BIOTECH CO., LTD.
- Assignee: ATOSSA THERAPEUTICS, INC.
- Correspondent: Jennifer L. Camacho, Law Office of Jennifer L. Camacho, 2800 E. Madison Street, Suite 201, Seattle, WA 98112. This correspondent recurs in this chain.
- Context: acquisition
2021-11-23 (executed) / recorded 2021-11-23 — Reel 058199/0053
- Conveyance: Assignment of Assignors Interest
- Assignor: QUAY, STEVEN C.
- Assignee: ATOSSA THERAPEUTICS, INC.
- Correspondent: Jennifer L. Camacho, Law Office of Jennifer L. Camacho, 2800 E. Madison Street, Suite 201, Seattle, WA 98112. This correspondent recurs in this chain.
- Context: acquisition
2021-11-23 (executed) / recorded 2021-11-23 — Reel 058199/0053
- Conveyance: Assignment of Assignors Interest
- Assignor: SUN, YaoLin, WANG, LUNGHU, WU, ChangJung
- Assignee: KRISAN BIOTECH CO., LTD.
- Correspondent: Jennifer L. Camacho, Law Office of Jennifer L. Camacho, 2800 E. Madison Street, Suite 201, Seattle, WA 98112. This correspondent recurs in this chain.
- Context: internal reorg
2021-11-23 (executed) / recorded 2021-11-23 — Reel 058199/0053
- Conveyance: Assignment of Assignors Interest
- Assignor: HUANG, ChuanDer, SUN, YaoLin, WANG, LUNGHU, WU, ChangJung
- Assignee: KRISAN BIOTECH CO., LTD.
- Correspondent: Jennifer L. Camacho, Law Office of Jennifer L. Camacho, 2800 E. Madison Street, Suite 201, Seattle, WA 98112. This correspondent recurs in this chain.
- Context: internal reorg
2021-11-30 (executed) / recorded 2021-11-30 — Reel 058253/0746
- Conveyance: Corrective Assignment to correct the conveying party name previously recorded.
- Assignor: KRISAN BIOTECH CO., LTD.
- Assignee: ATOSSA THERAPEUTICS, INC.
- Correspondent: Jennifer L. Camacho, Law Office of Jennifer L. Camacho, 2800 E. Madison Street, Suite 201, Seattle, WA 98112. This correspondent recurs in this chain.
- Context: internal reorg

Timeline diagram

timeline
    title Ownership of US 11261151
    2018 : Application filed by Atossa Therapeutics
    2020 : Assigned to Atossa Therapeutics Inc
    2021 : Krisan Biotech assigned to Atossa
         : Inventor Quay assigned to Atossa
         : Inventors to Krisan Biotech
         : Krisan Biotech assigned to Atossa
    2022 : Issued to Atossa Therapeutics Inc
    2025 : PTAB case IPR2025-00799 filed

NPE / troll-pattern signals

Shell-entity transfer — not present. All assignees appear to be operating companies involved in pharmaceutical development or were the original inventors' employers.
Known asserter in the chain — not present. None of the named assignees appear on public NPE lists.
Repeat correspondent across the chain — present. Jennifer L. Camacho of Law Office of Jennifer L. Camacho appears as the correspondent on all recorded assignments (Reel 051783/0477, Reel 058199/0053, Reel 058253/0746).
Cascading transfers — present. There are multiple assignments recorded on the same date (2021-11-23, Reel 058199/0053) involving different assignors but leading to Atossa Therapeutics, Inc., and a subsequent corrective assignment a week later (2021-11-30, Reel 058253/0746). This indicates a coordinated series of transfers.
Pre-litigation transfer — not present. The earliest litigation noted (IPR2025-00799) was filed in 2025, significantly after the most recent assignment activity in 2021.
Bankruptcy fire-sale — not present. No indication of bankruptcy for any of the entities in the assignment chain.
Privateering — unclear. There is no publicly available information in the patent record or Google Patents legal events to suggest privateering.
Defensive aggregator (anti-NPE) — not present. The chain does not terminate at a known defensive aggregator.

Verdict

Operating-company assertion
The ownership chain primarily shows transfers to and from Atossa Therapeutics, Inc., an operating company that develops products related to the patent's claims. While there are signs of cascading transfers and a repeat correspondent (Jennifer L. Camacho), these appear to be internal reorganizations and consolidations of ownership by the operating company rather than transfers to a licensing-only entity. The patent was also subject to a PTAB challenge that was settled, indicating active enforcement by Atossa.
Verification: https://assignmentcenter.uspto.gov/